Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Gary Korn who wrote (792)	12/25/1999 10:50:00 AM
From: William Partmann	Read Replies (1) \| Respond to of 10345

To all courtesy of Merrill Lynch: 1. We reiterate our Buy rating on Eln which remains our top pick for 2000; 2. We are confident that Eln will file its NDA for zinconotide before the year end. The approximate 800 volume application is in final stages. We expect the FDA to assign a priority review. 3. The FDA appears to be near final action of the NDA for Zonagren, to treat epilepsy and the PLA for Neurobloc, for cervical dystonia. The company appears to be on track for market launch next quarter. 4. Current quarter operating trends appear to be finishing strongly, paced by Zanaflex and Skelaxin. We believe Eln's 1999 revenue should reach $1 billion. Our fourth quarter estimate assumes a 38% gain. 5. Senior management and directors ave recently purchased over 1.25 MM shares 6. 12 month projection-$45.00. Merry Christmas Bill